Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases-Reference-Cited by-同舟云学术

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

Published:2013-05-09 Issue:1 Volume:1291 Page:14-32
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Ann. N.Y. Acad. Sci.

Author:

Lebwohl David¹,Anak Özlem²,Sahmoud Tarek³,Klimovsky Judith¹,Elmroth Ingrid²,Haas Tomas²,Posluszny Joseph³,Saletan Stephen³,Berg William³

Affiliation:

1. Novartis Pharmaceuticals Corporation; Florham Park New Jersey

2. Novartis Pharma AG; Basel Switzerland

3. Novartis Pharmaceuticals Corporation; East Hanover New Jersey

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/nyas.12122/fullpdf

Reference75 articles.

1. Afinitor (everolimus tablets for oral administration) Afinitor Disperz (everolimus tablets for oral suspension) East Hanover, NJ Novartis Pharmaceuticals Corporation 2012

2. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells;Sabers;J. Biol. Chem.,1995

3. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy;Yuan;J. Hematol. Oncol.,2009

4. Research and innovation in the development of everolimus for oncology;Lebwohl;Exp. Opin. Drug Discovery,2011

5. Targeting the mTOR signaling network for cancer therapy;Meric-Bernstam;J. Clin. Oncol.,2009

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A single-centre, double-blind, randomized, placebo-controlled, 2-arm study to evaluate the safety and efficacy of once-weekly Sirolimus (Rapamycin) on muscle strength and endurance in older adults following a 13-week exercise program.;2024-08-28

2. Model-informed precision dosing: State of the art and future perspectives;Advanced Drug Delivery Reviews;2024-08

3. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy;Signal Transduction and Targeted Therapy;2023-11-06

4. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of CXCR4 expression;International Journal of Molecular Medicine;2023-07-19

5. Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies;Nature Communications;2023-05-26